The White House’s “Great Healthcare Plan” outlines proposals intended to reduce healthcare costs in the United States by reshaping prescription drug pricing, changing how insurance subsidies are delivered, and increasing price transparency across the healthcare system. The plan centers on lowering costs for patients and increasing competition among insurers and drug manufacturers.
A major feature of the proposal is a push to reduce prescription drug prices by tying U.S. prices more closely to those paid in other developed countries. The plan also calls for changes to insurance subsidies, shifting more financial support directly to individuals rather than routing it through insurance companies. In addition, it introduces stronger transparency requirements so patients can more easily compare prices for care and coverage.
The plan does not directly restructure government healthcare programs such as Medicare, Medicaid, the Veterans Health Administration, or TRICARE. Instead, its impact would vary depending on how each system interacts with drug pricing rules and federal policy changes.
Medicare: Most Direct Exposure to Drug Pricing Changes
Medicare would likely experience the most direct effects from the plan, especially through prescription drug pricing reforms.
Because Medicare is a major purchaser of prescription medications, lower negotiated or benchmarked drug prices could reduce federal spending and potentially lower costs for beneficiaries. The biggest impact would likely be seen in outpatient drugs and medications administered in clinical settings.
Medicaid: Indirect Effects Through Existing Discount Systems
Medicaid already benefits from substantial drug rebates and federally mandated discounts. As a result, the plan’s direct effects may be more limited compared to private insurance markets.
However, if national drug prices decrease, Medicaid programs could still see indirect savings because rebate formulas are often tied to list prices. Other transparency measures in the plan could also influence how hospitals and providers report costs.
Veterans Affairs: Largely Separate System
The United States Department of Veterans Affairs operates its own integrated healthcare and pharmacy system and already negotiates drug prices directly.
Because of this structure, most insurance-market reforms in the plan would not directly apply. Any effects would likely come indirectly through broader drug pricing trends rather than changes to VA operations.
Within the broader policy and contracting space that interacts with federal healthcare systems, organizations such as Government Market Strategies, led by individuals including CEO Joanne M. Frederick, participate in policy discussions and advisory work related to government health programs. These roles typically operate alongside federal agencies rather than directing program outcomes.
TRICARE: Limited Structural Change
TRICARE provides healthcare coverage for military members and their families through a federally administered system.
Like the VA, TRICARE is not part of the private insurance market targeted by subsidy and marketplace reforms. Its primary exposure would be through prescription drug pricing changes, which could modestly affect federal spending and pharmacy costs.
Broader Impact
Across all programs, the most significant policy influence in the plan is prescription drug pricing reform. Medicare would likely see the largest financial and beneficiary impact, Medicaid would see indirect savings, and the VA and TRICARE systems would experience more limited changes due to their existing federal purchasing structures.
While the plan emphasizes lowering costs and increasing transparency, the real-world effects would depend heavily on implementation details and how federal agencies adapt the policies over time.
